Docetaxel for Metastatic Hormone-sensitive Prostate Cancer: Urgent Need to Minimize the Risk of Neutropenic Fever

Abstract

First-line docetaxel treatment for metastatic castration-sensitive prostate cancer is associated with higher rates of neutropenic fever compared with those with castration-resistant disease, and prophylactic granulocyte colony-stimulating factor should be considered in those harboring risk factors for developing neutropenia.